SAN FRANCISCO, May 10, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:
- Bank of America Merrill Lynch 2017 Health Care Conference
Gene Therapy & Editing Panel
May 17, 2017, 1:40 PM PT
Encore at Wynn Las Vegas, Las Vegas, NV
- UBS Global Healthcare Conference
May 22, 2017, 11:00 AM ET
Grand Hyatt, New York, NY
To access a live webcast of the corporate presentation at the UBS Global Healthcare Conference, please visit the Events & Presentations page within the Investors & News section of the Audentes website. A replay of the live webcast will remain available on the Audentes website for approximately 30 days following the conference. A webcast will not be available for the Gene Therapy and Editing Panel at the Bank of America Merrill Lynch 2017 Health Care Conference.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.
For more information regarding Audentes, please visit www.audentestx.com.
Thomas Soloway, CFO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-upcoming-investor-conferences-300454626.html
SOURCE Audentes Therapeutics, Inc.